Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive

Schizophrenia Bulletin

Volumn 42, Issue 3, 2016, Pages 744-752

  Mouchlianitis, Elias ^a,b   Bloomfield, Michael A P ^a,c   Law, Vincent ^a   Beck, Katherine ^b   Selvaraj, Sudhakar ^d   Rasquinha, Naresh ^e   Waldman, Adam ^a   Turkheimer, Federico E ^b   Egerton, Alice ^b   Stone, James ^a,b   Howes, Oliver D ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS   (United States)

^e Mental Health Division   (United Kingdom)

Author keywords

1H MRS; antipsychotics; glutamate; imaging and schizophrenia; neurochemistry; NMDA; psychosis; treatmentresistance

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; NEUROLEPTIC AGENT;

ADULT; ANTERIOR CINGULATE; ARTICLE; CHRONIC PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DSM-IV; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MALE; MENTAL PATIENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; CHRONIC DISEASE; CINGULATE GYRUS; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA;

EID: 84966350539     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv151     Document Type: Article

References (65)

1. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69: 776-786
2. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011; 31: 497-502
3. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000; 71: 373-384
4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry. 2000; 157: 514-520
5. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med. 1993; 23: 791-797
6. Kane JM. Addressing nonresponse in schizophrenia. J Clin Psychiatry. 2012; 73
7. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161: 1-56
8. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014; 205: 1-3
9. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012; 169: 1203-1210
10. Bartlett EJ, Brodie JD, Simkowitz P, et al. Effect of a haloperidol challenge on regional brain metabolism in neurolepticresponsive and nonresponsive schizophrenic patients. Am J Psychiatry. 1998; 155: 337-343
11. Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012; 32: 95-99
12. Wolkin A, Duncan E, Sanfilipo M, Wieland S, Cooper TB, Rotrosen J. Persistent psychosis after reduction in pre-And post-synaptic dopaminergic function. J Neural Transm Gen Sect. 1994; 95: 49-61
13. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000; 97: 8104-8109
14. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-Treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997; 54: 959-965
15. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex γ-Aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012; 69: 449-459
16. Theberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-Treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002; 159: 1944-1946
17. Theberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007; 191: 325-334
18. Stone JM, Day F, Tsagaraki H, et al.; OASIS. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 2009; 66: 533-539
19. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010; 15: 629-636
20. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011; 69: 19-27
21. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC. Regional decoupling of N-Acetyl-Aspartate and glutamate in schizophrenia. Neuropsychopharmacol. 2012; 37: 2635-2642
22. Reid MA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010; 68: 625-633
23. Wood SJ, Yucel M, Wellard RM, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res. 2007; 94: 328-331
24. Ongur D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008; 64: 718-726
25. Aoyama N, Theberge J, Drost DJ, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011; 198: 448-456
26. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-Analysis of 1H-MRS studies. Schizophr Bull. 2013; 39: 120-129
27. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014; 75: 11-13
28. Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012; 37: 2515-2521
29. Szulc A, Konarzewska B, Galinska-Skok B, et al. Proton magnetic resonance spectroscopy measures related to short-Term symptomatic outcome in chronic schizophrenia. Neurosci Lett. 2013; 547: 37-41
30. Barksdale KA, Lahti AC, Roberts RC. Synaptic proteins in the postmortem anterior cingulate cortex in schizophrenia: relationship to treatment and treatment response. Neuropsychopharmacology. 2014; 39: 2095-2103
31. Lahti AC, Holcomb HH, Weiler MA, et al. Clozapine but not haloperidol Re-establishes normal task-Activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2004; 29: 171-178
32. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry. 2003; 53: 601-608
33. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001; 50: 898-911
34. Gardner DM, Murphy AL, O Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010; 167: 686-693
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276
36. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162: 441-449
37. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 11th ed. London, UK: Wiley-Blackley; 2012
38. Stone JM, Pepper F, Fam J, et al. Glutamate, N-Acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl). 2014; 231: 2107-2116
39. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14: 260-264
40. Wagenmakers EJ, Farrell S. AIC model selection using Akaike weights. Psychon Bull Rev. 2004; 11: 192-196
41. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012; 201: 481-485
42. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003; 64: 30-34
43. Harrison J, Janlov M, Wheeler AJ. Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci. 2010; 32: 503-511
44. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. 2007; 33: 1221-1224
45. Alessi-Severini S, Le Dorze JA, Nguyen D, Honcharik P, Eleff M. Clozapine prescribing in a Canadian outpatient population. PLoS One. 2013; 8: e83539
46. Schwieler L, Engberg G, Erhardt S. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse. 2004; 52: 114-122
47. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012; 165: 1543-1555
48. Hons J, Vasatova M, Cermakova E, Doubek P, Libiger J. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J Psychiatr Res. 2012; 46: 811-818
49. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001; 41: 237-260
50. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009; 15: 2550-2559
51. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-Aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007; 78: 69-108
52. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005; 62: 985-994
53. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27: 11496-11500
54. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA psychiatry. 2013; 70: 1057-1066
55. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacol. 2011; 36: 1781-1791
56. Choi YK, Gardner MP, Tarazi FI. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2009; 19: 77-84
57. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Longterm effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003; 306: 1145-1151
58. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015; 29: 97-115
59. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999; 33: 523-533
60. Poels EMP, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014; 19: 20-29
61. Merritt K, McGuire P, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry. 2013; 4: 151
62. Snyder J, Wilman A. Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T. J Magn Reson. 2010; 203: 66-72
63. Bustillo JR, Chen H, Jones T, et al. Increased glutamine in patients undergoing long-Term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. JAMA Psychiatry. 2014; 71: 265-272
64. Theberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003; 160: 2231-2233
65. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med. 2004; 51: 904-912